Login to Your Account



Deals And M&A NEWS
DUBLIN – Stem cell developer Tigenix NV is entering the cardiology arena through the acquisition of Madrid, Spain-based Coretherapix SL in a deal worth up to €266.7 million (US$291 million), the vast bulk of which is loaded toward the back end.
Merck & Co. Inc. turned to a small Israeli biotech, Ccam Biotherapeutics Ltd., to pad its immuno-oncology (I-O) pipeline with a next-generation monoclonal antibody (MAb) targeting the immune checkpoint protein known as carcinoembryonic antigen-related cell adhesion molecule 1, or CEACAM1.
HONG KONG – Newly listed Chinese biopharmaceutical company Shenyang-based 3SBio Inc. acquired small-molecule maker Zhejiang Wansheng Pharmaceutical Co. Ltd. for ¥528 million (US$85 million) to complement its oncology and nephrology pipeline.
More Deals And M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: